Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07009886 · ClinicalTrials.gov registry record · NA

Development of an Educational Patient Decision Aid (Treatments in Advanced Cancer - Decision Aid, TA-DA) to Promote Shared Decision Making for Third-line or Beyond Palliative Systemic Therapy

A NA study of Advanced Cancer, sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
NA
Development phase
155
Enrollment target
1
Study location

NCT07009886: Recruiting NA study of Advanced Cancer, sponsored by M.D. Anderson Cancer Center.

NCT07009886 is a NA study of Advanced Cancer that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 155 participants, below the 245-participant average among 122 other Advanced Cancer trials with a reported enrollment target (37% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07009886, a NA study of Advanced Cancer, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
NA
Development phase
155 participants
Enrollment target
1
Study location

Study Summary

To develop an educational patient decision aid for advanced cancer patients to prepare them to have conversations with their clinicians about treatment options (Treatments in Advanced cancer - Decision Aid, TA-DA).

Primary Outcome

Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

Conditions Studied

Interventions

  • OTHER Communication

Study Locations (1)

Texas

  • The University of Texas M. D. Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 155 participants
Start Date 2025-07-10
Est. Completion 2030-07-31
Phase NA
M.D. Anderson Cancer Center

2,692 total trials

What NCT07009886 shows while recruiting

NCT07009886 is an interventional study that assigns participants to a tested intervention. The registered 155 participants enrollment target is mid-sized for trials with a published cap, below the 245-participant average among 122 other Advanced Cancer trials with a reported enrollment target (37% lower).

The record links to 1 condition, with Advanced Cancer appearing as the primary indexed condition, and to 1 intervention - of which Communication is the first listed.

NCT07009886 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT07009886 about?

NCT07009886 is a clinical study titled "Development of an Educational Patient Decision Aid (Treatments in Advanced Cancer - Decision Aid, TA-DA) to Promote Shared Decision Making for Third-line or Beyond Palliative Systemic Therapy". To develop an educational patient decision aid for advanced cancer patients to prepare them to have conversations with their clinicians about treatment options (Treatments in Advanced cancer - Decision Aid, TA-DA).

What is the current status of trial NCT07009886?

This trial is currently recruiting. It is a NA study. The enrollment target is 155 participants. The study started on 2025-07-10. Estimated completion is 2030-07-31.

What conditions does trial NCT07009886 study?

This clinical trial studies the following conditions: Advanced Cancer.

What interventions are being tested in trial NCT07009886?

The interventions under investigation include: Communication (OTHER).

Who is sponsoring clinical trial NCT07009886?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07009886 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Advanced Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07009886's enrollment target sits among peer trials

155 43rd of 122 higher than 80 of 122 other Advanced Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Advanced Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03223610 · 155 participants · Phase 1

    Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

  • NCT05072483 · 155 participants

    Natural History Study of CADASIL

  • NCT05086497 · 155 participants · NA

    WBSI Guided Personalized Delivery of TTFields

  • NCT05412069 · 155 participants · NA

    Trial to Evaluate Fecobionics in Fecal Incontinence (FI) (NORMAL and ABNORMAL-FI)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07009886, the US trial registry maintained by the National Library of Medicine. NCT07009886 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.